F
François Bertucci
Researcher at Aix-Marseille University
Publications - 585
Citations - 24168
François Bertucci is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 75, co-authored 505 publications receiving 20261 citations. Previous affiliations of François Bertucci include French Institute of Health and Medical Research & University of the Mediterranean.
Papers
More filters
Journal ArticleDOI
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.
Emmanuelle Charafe-Jauffret,Christophe Ginestier,Flora Iovino,Julien Wicinski,Nathalie Cervera,Pascal Finetti,Min-Hee Hur,Mark E. Diebel,Florence Monville,Julie Dutcher,Marthy Brown,Patrice Viens,Luc Xerri,François Bertucci,Giorgio Stassi,Gabriela Dontu,Daniel Birnbaum,Max S. Wicha +17 more
TL;DR: It is shown that ALDEFLUOR-positive cells are responsible for mediating metastasis and the hierarchical organization of immortalized cell lines, establish techniques that can facilitate the characterization of regulatory pathways of CSCs, and identify potential stem cell markers and therapeutic targets.
Journal ArticleDOI
Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
Emmanuelle Charafe-Jauffret,Christophe Ginestier,Flora Iovino,Carole Tarpin,Mark E. Diebel,Benjamin Esterni,Gilles Houvenaeghel,Jean-Marc Extra,François Bertucci,François Bertucci,Jocelyne Jacquemier,Luc Xerri,Luc Xerri,Gabriela Dontu,Giorgio Stassi,Yi Xiao,Sanford H. Barsky,Daniel Birnbaum,Patrice Viens,Max S. Wicha +19 more
TL;DR: AlDH1 expression represents the first independent prognostic marker to predict metastasis and poor patient outcome in IBC and suggests that the metastatic, aggressive behavior of IBC may be mediated by a CSC component that displays ALDH enzymatic activity.
Journal ArticleDOI
Gene expression profiling of breast cell lines identifies potential new basal markers
E Charafe-Jauffret,Christophe Ginestier,Florence Monville,Pascal Finetti,José Adélaïde,Nathalie Cervera,S Fekairi,Luc Xerri,Jocelyne Jacquemier,David Jérémie Birnbaum,François Bertucci +10 more
TL;DR: The BCL basal/luminal signature correctly re-classified the published series of tumour samples that originally served to identify the molecular subtypes, suggesting that the identified markers should be useful for tumour classification and might represent promising targets for disease management.
Journal ArticleDOI
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Emilie Mamessier,Aude Sylvain,Marie-Laure Thibult,Gilles Houvenaeghel,Jocelyne Jacquemier,Rémy Castellano,Anthony Gonçalves,Pascale Andre,François Romagné,Gilles Thibault,Patrice Viens,Daniel Birnbaum,François Bertucci,Alessandro Moretta,Daniel Olive +14 more
TL;DR: The data show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity, highlighting the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitUMor immunity.
Journal ArticleDOI
How basal are triple-negative breast cancers?
François Bertucci,Pascal Finetti,Nathalie Cervera,Benjamin Esterni,Fabienne Hermitte,Patrice Viens,Daniel Birnbaum +6 more
TL;DR: It is revealed that TN BCs represent a more heterogeneous group than basal BCs, including basal and nonbasal tumors very different both at the histoclinical and molecular level, notably for mRNA expression of molecules targeted by specific therapies under evaluation in clinical trials.